{"name":"MODEL","title":"","children":[{"id":"in silico","name":"in silico","presenterLast":"in silico","children":[{"id":608,"name":608,"title":"Comprehensive evaluation of antibody-drug conjugate targets for drug development across tumor types: Analysis from TCGA","presenterFirst":"Roman","presenterLast":"Groisberg","keywords":"Drug discovery;RNA;Gene expression profiling;Gene expression analysis","target":"multiple","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"no","model":"in silico"},{"id":4311,"name":4311,"title":"Synthesis and evaluation of sugar alcohol based molecules for drug conjugation and delivery","presenterFirst":"Yumei","presenterLast":"Huang","keywords":"Drug delivery;Polyethylene glycol;Antibody Drug Conjugate;Hydrophilic linker","target":"NA","tumor":"NA","sage":"linker","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"preclinical in vitro","name":"preclinical in vitro","presenterLast":"preclinical in vitro","children":[{"id":5865,"name":5865,"title":"Synergistic antileukemic activity of the antibody-drug conjugate (IMGN779) combined with PARP inhibition in preclinical human acute myeloid leukemia models","presenterFirst":"Eunice","presenterLast":"Wang","keywords":"PARP;Antibody;Leukemias: acute myeloid;DNA damage response","target":"CD33","tumor":"leukemia","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical in vitro"},{"id":6013,"name":6013,"title":"Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL)","presenterFirst":"Francesco","presenterLast":"Bertoni","keywords":"Lymphoma: non-Hodgkin's lymphoma;Anticancer therapy;Resistance;Targeted therapy","target":"CD37","tumor":"lymphoma","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6245,"name":6245,"title":"Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma","presenterFirst":"Adam","presenterLast":"Cheuk","keywords":"Antibody;Fibroblast growth factor receptor 4;Rhabdomyosarcoma;Anticancer therapy","target":"FGFR4","tumor":"sarcoma_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6250,"name":6250,"title":"Development of an HPLC method for the assessment of hydrophobicity of ADC payloads","presenterFirst":"Ilona","presenterLast":"Pysz","keywords":"Antibody;Drug Congugate;Payload Hydrophobicity;HPLC Assay","target":"NA","tumor":"NA","sage":"payload","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6326,"name":6326,"title":"CovisoLinK: New bacterial transglutaminase Q-Tag substrate for the development of site specific antibody-drug conjugates","presenterFirst":"Sandrine","presenterLast":"Valsesia-Wittmann","keywords":"Antibody Engineering","target":"HER2","tumor":"breast","sage":"linker","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6484,"name":6484,"title":"Development of next-generation antibody-drug conjugates for resistant HER2-positive tumors","presenterFirst":"Vincent","presenterLast":"Lacasse","keywords":"Cancer therapy;HER-2;Antibody-drug conjugate;Drug delivery","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6765,"name":6765,"title":"Identifying an optimal site for linker conjugation of the taccalonolides, novel microtubule stabilizing drugs","presenterFirst":"April","presenterLast":"Risinger","keywords":"Tubulin;Drug resistance;Microtubule-interfering agents;Natural product","target":"NA","tumor":"NA","sage":"payload","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":9288,"name":9288,"title":"Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer","presenterFirst":"Ricarda","presenterLast":"Hoffmann","keywords":"Breast cancer;Antibody-drug conjugate;Trastuzumab;Ribosome-inhibitor","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"preclinical xeno","name":"preclinical xeno","presenterLast":"preclinical xeno","children":[{"id":531,"name":531,"title":"Antibody-drug conjugate targeting glypican-1 shows potent antitumor effect in pancreatic cancer","presenterFirst":"Satoshi","presenterLast":"Serada","keywords":"Pancreatic cancer;Antibody;Drug delivery","target":"GPC1","tumor":"pancreas","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":2593,"name":2593,"title":"Anti-M\u00fcllerian hormone type II receptor (AMHRII), a cancer target for GM103, a novel antibody-drug conjugate (ADC)","presenterFirst":"Jean-Marc","presenterLast":"Barret","keywords":"Targeted drug delivery;Antibody Drug Conjugate;AMHRII;Antitumor agents","target":"AMHRII","tumor":"ovary_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3239,"name":3239,"title":"Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors","presenterFirst":"Francesca","presenterLast":"Zammarchi","keywords":"Targeted drug delivery;Cancer","target":"AXL","tumor":"tnbc_renal_pancreas","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3267,"name":3267,"title":"ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors","presenterFirst":"Francesca","presenterLast":"Zammarchi","keywords":"Targeted drug delivery;Tumor targeting","target":"DLK-1","tumor":"neuroblastoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3284,"name":3284,"title":"Development of novel formats of anti-AXL ADCs","presenterFirst":"Maria","presenterLast":"Jaramillo","keywords":"Antibody;Axl;antibody drug conjugate (ADC);Targeted drug delivery","target":"AXL","tumor":"breast_ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3963,"name":3963,"title":"The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts","presenterFirst":"Kristopher","presenterLast":"Bosse","keywords":"Neuroblastoma;Antibody-drug conjugate;Pyrrolobenzodiazepines;Glypican 2","target":"GPC2","tumor":"neuroblastoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4020,"name":4020,"title":"PD-L1 antibody drug conjugate for cancer immune-chemo combination therapy","presenterFirst":"Samaresh","presenterLast":"Sau","keywords":"Checkpoint;Antibody;Imaging;Immunotherapy","target":"PD-L1","tumor":"tnbc_lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4350,"name":4350,"title":"Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates","presenterFirst":"Rui","presenterLast":"Wu","keywords":"Vascular targeting;anti-endoglin ADC;Antitumor effect","target":"endoglin","tumor":"ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4413,"name":4413,"title":"Development of anti-Globo H ADC against cancer","presenterFirst":"Wei-Ting","presenterLast":"Sun","keywords":"Cancer;antibody drug conjugation;globo H","target":"Globo-H","tumor":"ovary_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5947,"name":5947,"title":"Targeting the EphA2-ligand binding domain for the design of innovative cancer therapeutics","presenterFirst":"Parima","presenterLast":"Udompholkul","keywords":"EphA2;Therapeutics;Peptidomimetics;Cancer","target":"Epha2","tumor":"prostate_pancreas_melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5975,"name":5975,"title":"Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells","presenterFirst":"Wan-Chen","presenterLast":"Wei","keywords":"Breast cancer;HER-2;Metformin;T-DM1","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6172,"name":6172,"title":"An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC","presenterFirst":"Louise","presenterLast":"Koopman","keywords":"Non-small cell lung cancer;AXL;EGFR tyrosine kinase inhibitor resistance;antibody-drug conjugate","target":"AXL","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6317,"name":6317,"title":"FGFR signaling facilitates recurrence of minimal residual disease post trastuzumab emtansine treatment in breast cancer","presenterFirst":"Saeed Salehin","presenterLast":"Akhand","keywords":"Drug resistance;Recurrence;Tyrosine kinase inhibitor;Targeted therapy","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7656,"name":7656,"title":"ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma <i>in vivo</i>","presenterFirst":"Puey Ling","presenterLast":"Chia","keywords":"Antibody;Novel anticancer agents;In vivo;Mesothelioma","target":"EGFR","tumor":"mesothelioma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":8204,"name":8204,"title":"\u03b1<sub>3</sub>\u03b2<sub>1</sub>-Integrin targeted DM1 micellar prodrug for targeted therapy against ovarian cancer","presenterFirst":"Xiaocen","presenterLast":"Li","keywords":"Gynecological cancers: ovarian;DM1;micellar prodrug;drug delivery","target":"HER2","tumor":"ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]}]}
